Oncology Highlights – 30/07/2018

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Oncology Highlights – 30/07/2018

Keytruda, the First Anti-PD-1 Therapy for Advanced Melanoma, Approved in China Merck announced that Keytruda, Merck’s anti-PD-1 therapy, has been approved by the China National Drug Administration ...

Jul 17, 2018

transthyretin amyloidosis
Notizia

Arming antibiotics with a vaccination-like immune response Harnessing the ability of the body’s immune system has already well-tried to be effective in treating cancer. Marcos Pires, Ph.D., a Lehigh associate professor of biochemistry performed a test on it. To make it worse, these microorganism perpetually evolv...

Find More
transthyretin amyloidosis
Idera’s drug; CRISPR increase risk; Juvenescence grabbed USD 50M; AstraZeneca, Lilly terminates

Idera's dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial carried on adults with dermatomyositis. Data has shown that the drug was meant to block TLR 7, 8 and 9 but failed to beat placebo in making a s...

Find More
transthyretin amyloidosis
Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation

Axovant rely on new gene therapy, Rise in Shares  Roivant Neuro Company has licensed Oxford Biomedica’s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson’s disease (PD). Spark Therapeutics’ Former CTO Fraser Wright, Ph.D has been hired as its new CTO. Axovant expects to stimulate a phase 1/2 dose escalation stu...

Find More

More Views & Analysis

Notizia
Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating

ImmusanT upgrading the management ahead of phase 2 celiac vaccine trial ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo’s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer. The management is also boosted with new VPs in program management and clinical oper...

Find More

Entasis
Business Cocktail

Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains. The pair is now entering into a new license agreement with a potential deal worth of around USD 484.7 million....

Find More

transthyretin amyloidosis
Atara Biotherapeutics hires; Minor effects of multiple genes determine migraine risk; Celgene set to refile ozanimod

Atara Biotherapeutics hires ex-Genentech SVP to lead its global R&D program Atara Biotherapeutics recently hired Dietmar Berger, M.D., Ph.D., as its R&D global head. During the time in Genentech, Berger was involved in the approval of several drugs including the PD-L1 checkpoint inhibitor Tecentriq. Berger w...

Find More

Delveinsight
Horizon Discovery declines Abcam’s USD 367 million takeover bid

Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in gene editing technique and has issued a strong rejection to the offer of Abcam. Horizon’s board believes that the bid unde...

Find More

transthyretin amyloidosis
Notizia

FDA still not completely satisfied with Kamada’s inhaled AAT drug(Synthetic Biologics) Kamada is stuck again with a new obstacle in its way to bring the first inhaled treatment for alpha-1 antitrypsin (AAT) deficiency in the market as an alternative to currently present intravenous drugs. The company specializes in ...

Find More

transthyretin amyloidosis
Phase 1 data of CYC065; Lysogene delays phase 3 study; Genetic disorders Diagnosis; PD-1 resistance in melanoma patients

Positive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CD...

Find More

AAV Vectors are the leading viral vectors for gene delivery to treat a variety of human diseases. Ad.....

Find More

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More

Primary Progressive Aphasia (PPA) is a rare neurological disorder that results from the damages to t.....

Find More

West Nile Disease is a disease caused by the West Nile Virus, a flavivirus associated with the virus.....

Find More

COVID-19 transforms healthcare facets at an unprecedented pace. Based on emerging technology, we can.....

Find More

Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of.....

Find More